# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹237 Cr** Q4 FY26 (+9%) · **₹991 Cr** FY26 (+26%) * **EBITDA:** **₹69 Cr** Q4 FY26 (+27%) · **₹288 Cr** FY26 (+61%) * **EBITDA Margin:** **29.3%** Q4 FY26 (+420 bps) · **29.0%** FY26 (+630 bps) * **PAT:** **₹40 Cr** Q4 FY26 (+40%) · **₹170 Cr** FY26 (+83%) * **Return Ratios:** **35.8%** ROCE · **26.9%** ROE (as of Mar-31-2026) * **Leverage & Efficiency:** **0.3x** Debt to Equity · **1.7x** Fixed Asset Turnover ## B. Revenue & Profitability * **Resilient Growth Profile:** Robust annual top-line expansion achieved despite external pressures, supported by a diversified customer base and disciplined execution. * **Profitability Surge:** Significant bottom-line outperformance and margin expansion driven by operational efficiencies and a **62% increase** in Cash PAT. * **Subsidiary Dynamics:** UK performance impacted by a transition toward complex, milestone-based projects; management advises viewing UK and UAE margins on a combined basis due to integrated service delivery. ## C. Margin Expansion * **Sustainability & Outlook:** Management confirms current high-margin profile is sustainable annually, with further upside expected as semiconductor and Abu Dhabi capacities scale. * **Operational Leverage:** Substantial year-on-year margin improvement reflects strong operational planning and a shift toward higher-value project mix. ## D. Capital Allocation * **Strategic Optionality:** Board approved an enabling resolution to raise up to **INR 500 crores** to maintain flexibility for potential high-scale, capital-intensive projects. * **Funding Stance:** The fundraising resolution is characterized as a procedural annual measure rather than an immediate capital requirement. --- # 2. Healthcare Segment Performance ## A. Key Figures * **Healthcare Revenue:** **₹393 Cr** FY26 (+139%) · **₹113 Cr** Q4 FY26 (+101%) * **Revenue Contribution:** **40%** of total mix (vs. 21% YoY) ## B. Pen Injector Growth & Capacity * **Aggressive Capacity Expansion:** Management is rapidly scaling infrastructure, adding **5 Cr** units of capacity by Q2 FY27 to reach a total of **8 Cr** pens to meet surging demand for insulin and auto-injectors. * **Utilization Targets:** Aiming for **60% to 70%** utilization of insulin pen capacity, with total production expected to reach **4–6 Cr** pens within the next **30 months**. * **Strategic Scaling:** The healthcare segment is maintaining triple-digit annual growth, with the Abu Dhabi expansion cited as a critical lever for future global scaling. ## C. GLP-1 & Semaglutide Market Entry * **Global Regulatory Validation:** Successful commercial launch of Semaglutide pens in India and Canada, alongside tentative **D. S. approval**, validates manufacturing standards in highly regulated markets. * **Strategic Asset Positioning:** The company is positioning itself as a primary supply partner for the GLP-1 market, one of the world's fastest-growing drug segments. * **Future Pipeline:** While no agreements are yet signed with **innovator companies**, regular supplies for GLP-1 products are expected to drive a significant revenue ramp-up through FY27. ## D. Healthcare Revenue Mix & Segment Shift * **Structural Pivot:** Healthcare has emerged as the primary growth engine, more than doubling its revenue contribution as the consumer division saw a **9% decline**. * **Diversified Growth:** Beyond pens, the company is commercializing **eye-applicators** as import substitutes and has scaled UK-based R&D to develop next-generation drug delivery devices. * **Long-term R&D:** Sustained outperformance is attributed to multi-year investments in proprietary pen injector platforms and drug delivery IP. --- # 3. Manufacturing & Capacity ## A. Key Figures * **Operational Efficiency:** **47.6%** FY26 machine utilization (+540 bps) · **45%** current OEE * **Healthcare Metrics:** **8%** rejection rate (vs. 30% prior) · **35 ppm** current speed (vs. 80 ppm design) * **Export Contribution:** **68%** of total revenue * **Asset Turnover:** **2x to 2.5x** fixed asset turnover target ## B. Production Ramp-up * **Capacity Scaling:** Management is aggressively scaling production lines to reach peak unit targets by late Q2, with the current order book already frozen for the fiscal year. * **Execution Risk:** Future performance hinges on the successful August installation of a new line and the technical ramp-up of highly complex production processes. * **Output Optimization:** Targeted production speeds for new lines are set to reach **65-67 parts per minute** by year-end to meet annual capacity goals. ## C. Operational Efficiency * **Utilization Gains:** Overall machine utilization saw a healthy year-on-year increase, though newer units installed in March are still maturing toward optimal speeds. * **Healthcare Quality Turnaround:** Significant operational de-risking achieved through a drastic reduction in rejection rates, despite the segment still operating at less than half of its design speed. ## D. Global Facility Expansion * **Specialized Capacity:** A dedicated **2.5 Cr capacity** unit is being finalized for July/August, focused exclusively on the global **Semaglutide** market. * **Strategic Footprint:** Plans underway for a **₹100 Cr** greenfield facility in South India for consumer electronics; Abu Dhabi remains a strategic hub for lower costs and international talent. * **Future Growth:** Exploration of additional device capacities is ongoing for markets that cannot be serviced by existing India or UAE hubs, funded via internal discipline rather than immediate capital raises. --- # 4. Consumer & Industrial Segments ## A. Key Figures * **Consumer Revenue:** **₹102 Cr** Q4 (-31%) · **₹511 Cr** FY26 (-9%) * **Industrial Revenue:** **₹22 Cr** Q4 (+60%) · **₹87 Cr** FY26 (+41%) ## B. Consumer Demand Trends * **Geopolitical & Macro Headwinds:** Segment performance was hampered by weak home furnishing demand in **C. S./Europe** and regional conflict-related cancellations in the **Middle East**. * **Portfolio Diversification:** Management is actively mitigating cyclical downturns by **adding new products** to the portfolio to capture future recovery. ## C. Industrial Vertical Growth * **Portfolio Diversification:** Robust double-digit growth driven by successful expansion into **power tools and LED light components**, moving beyond core automotive exposure. * **Infrastructure Momentum:** New business confirmations in lighting and infrastructure applications underpinned the significant Q4 and full-year revenue surge. ## D. Electronics & Semiconductors * **Strategic Entry:** Commenced commercial supplies for consumer electronics in Q4 FY26, entering a high-complexity ecosystem with limited global competition. * **Semiconductor Supply Chain:** Secured a supply agreement with a **Korean firm** for semiconductor trays; positioned as a high-volume **consumable** for Indian OSAT and Fab players. * **Technical Moat:** Order wins are driven by specialized expertise in **conductive plastics**, a high-barrier material requirement for semiconductor packaging. * **Scale & Profitability:** Consumer electronics requires a revenue scale of **₹1.5 Cr to ₹2 Cr** to offset high technical overheads and achieve favorable ROCE. * **Growth Hierarchy:** Management ranks the **Semiconductor vertical** as its second-largest scale-up opportunity, ahead of the Industrial and Consumer segments. --- # 5. Customer & Market Strategy ## A. Key Figures * **New Order Value:** **₹423 Cr** Pen Injectors (Domestic) (4-Year Duration) * **Market Share (Canada):** **70%** of filings by top six filers utilize Shaily devices ## B. Order Book Status * **Significant Domestic Win:** Secured a major multi-year contract for pen injectors with a large domestic commerce entity, though specific quarterly run rates remain confidential. * **Long-term Opportunity:** Management anticipates a specific client engagement to scale significantly over a **5-year horizon**, reinforcing the long-term growth trajectory. ## C. Export & Geography Mix * **Global Expansion Roadmap:** Commercial launches in Brazil are imminent (targeted **May/June 2026**), with subsequent entries planned for Turkey and Mexico. * **Regional Specialization:** Middle East operations will pivot exclusively toward Healthcare, with dedicated regional hiring commencing between **Q1 FY26 and October**. * **Strategic Market Entry:** Actively exploring opportunities in China and positioning for the "first wave" of approvals in the Brazilian market. ## D. Competitive Positioning * **Dominant Canadian Footprint:** Established a commanding presence in Canada, where both pharmaceutical companies with current approvals exclusively use Shaily devices. * **Semiconductor Advantage:** Positioned as the sole Indian manufacturing partner for its current semiconductor customer, leveraging early-mover status against international incumbents. * **Import Substitution Trend:** Anticipates a shift toward local sourcing for semiconductor chip trays, challenging the current dominance of manufacturers in Korea, China, and the Philippines. ## E. Strategic Partnerships * **Innovator Pipeline:** Advanced discussions are underway regarding new projects with global innovators, signaling potential high-value breakthroughs in the pipeline. * **Domestic Validation:** Positive market reception for generic semaglutide products by partners Dr. Reddy’s and Torrent bolsters Shaily’s reputation for quality and reliability. --- # 6. Risks & Operational Factors ## A. Key Figures * **Investment Lead Times:** **18–24 months** for complex production lines (vs. 12 months previously) * **Regulatory Barriers:** **24–36 months** for new supplier filing · **70%–80%** of original program cost for additional devices * **Development Costs:** **₹100–150 Cr** typical range for generic company programs ## B. Geopolitical & Logistics * **Macro Headwinds:** Heightened global trade tensions and corridor disruptions are driving raw material inflation and logistical friction in export routes. * **Project Resilience:** Management maintains commitment to the Abu Dhabi expansion, utilizing **built-in timeline buffers** to absorb short-term geopolitical shocks. * **Competitive Positioning:** Definitive cost-competitiveness benchmarking against Chinese market participants remains challenging under current conditions. ## C. Capacity & Execution * **Volume Constraints:** Healthcare pen device output fell slightly short of targets due to existing capacity limitations, despite robust demand. * **Leadership Expansion:** Strengthened operational oversight with the appointment of a new **Chief Operating Officer for Healthcare** to manage scaling. * **Supply Chain Risks:** Early-phase production ramp-up for Canadian clients carries execution risk; any deviation from production plans threatens supply consistency. * **Machinery Bottlenecks:** Complexity of equipment and a consolidated global supplier base have significantly extended the investment-to-commissioning cycle. ## D. Regulatory & Compliance * **High Entry Barriers:** Significant time and capital requirements for regulatory filings in regulated markets like Canada act as a defensive moat against new entrants. * **Product Quality Track Record:** Post-launch performance remains strong with zero device failures; only **two minor complaints** (user error and printing) reported across Canada and India. --- # 7. Guidance & Outlook ## A. Key Figures * Target Supply Volume (FY27): 36 million pen units * **Optimum Efficiency Target:** **60% to 65%** utilization over **2 to 3 years** ## B. Long-term Revenue Potential * **Strategic Growth Pillars:** Management is prioritizing the healthcare vertical, the **Abu Dhabi facility** development, and the ramp-up of **consumer electronics and semiconductor tray** programs. * **Revenue Modeling:** Guidance is anchored to the total revenue potential of the full **8 crore pen capacity** rather than incremental scaling steps. * **Segment Recovery:** Strategic focus includes restoring momentum within the home furnishing segment alongside high-tech expansions. ## C. Future Capacity Timeline * **Phased Expansion:** Following an existing addition of **2.5 crore** units, the company is tracking toward significant capacity growth by the end of the FY28 period. * **Operational Learning Curve:** Future phases, specifically the next **2.5 crore unit** expansion, are expected to achieve improved yields and lower initial rejection rates due to institutional learning.